Jiangsu Chia-tai Tianqing Pharmaceutical secured exclusive rights to develop, produce and bring to market BioLineRx's BL-8030, an oral hepatitis C drug candidate, in China and Hong Kong. BioLineRx will keep the drug's development and commercialization rights in other parts of the world. The deal entitles BioLineRx to as much as $30 million in upfront and milestone fees plus sales royalties.

Related Summaries